Actualités

NVIDIA's latest 13F filing does not tell the story it seems to at first glance. The apparent divergence in its CoreWeave and Nebius holdings is a prime example.

Generate Biomedicines, Inc. (NASDAQ:GENB) is one of the best low priced biotech stocks to invest in. On April 13, H.C. Wainwright initiated coverage of Generate Biomedicines, Inc. (NASDAQ:GENB) with a Buy rating, setting a $16 price target. The firm told investors in a research note that the stock has fallen over 20% even as GB-0895 advanced into […]

Generate Biomedicines: Recent Trading Moves And Core Business Snapshot Generate Biomedicines (GENB) has seen recent share price pressure, with a 10% decline over the past week and a similar move over the past month, bringing the latest close to US$11.21. For context, the company reports revenue of US$31.893 million alongside a net loss of US$249.523 million, reflecting the costs of developing its generative biology platform and early stage pipeline of protein based therapeutics. See our...

Health care stocks rose late Friday afternoon, with the NYSE Health Care Index adding 1.3% and the S